Full Breakdown
WTA Mandates One-Time Genetic Test for All Female Tour Players
7/20/2026, 9:15:01 PM
New Genetic Eligibility Rule for Women's Tennis
The Women’s Tennis Association (WTA) announced that, beginning on Tuesday, every player who wishes to compete on the WTA Tour must undergo a one-time test for the SRY gene, which is located on the Y chromosome and determines male biological characteristics. The test may be performed via cheek swab, blood or saliva sample. A negative result (no SRY gene detected) will allow competition; a positive result will trigger further medical assessment before eligibility can be confirmed. The screening program is slated to start in 2026.
Background & Policy Shift
The updated rule replaces the policy last revised in 2024, which permitted transgender women to play if they declared a female gender identity and maintained testosterone levels below 2.5 nmol/L for two consecutive years. The WTA noted that no transgender women are currently active at any level of professional tennis. Similar one-time gene-testing requirements have recently been adopted by World Athletics (effective September 2025) and World Boxing (May 2025). In March, the International Olympic Committee also announced that only athletes whose gender is confirmed by a one-time test will be eligible for female-category Olympic events.
Official Statements & Responses
The WTA described the policy as a measure to “promote equal athletic opportunities in women’s professional tennis and maintain fair competition for all players participating in WTA tournaments.” The governing body emphasized that the change follows a periodic review process that began with the policy’s original introduction in 1975. It also highlighted a “comprehensive player engagement program” and assured that “all appropriate confidentiality and data privacy safeguards” will be applied. The association acknowledged the issue’s sensitivity and pledged to treat all athletes with dignity.
Criticism & Opposition
Transgender advocacy groups have labeled the requirement discriminatory, arguing that exclusion based on genetics undermines inclusion. Critics of transgender participation contend that physiological advantages acquired during male puberty are not fully mitigated by transition, a view echoed by some former players. The debate reflects broader tensions in sport over balancing fairness with rights for transgender athletes.
Verbatim Quotes
- “Eligibility to participate in WTA tournaments will be confirmed through a required, one-time screening process for the SRY gene,” — WTA spokesperson, Reuters
- “Player screening will begin in 2026, following all appropriate confidentiality and data privacy safeguards and concurrent with a comprehensive player engagement program.” — WTA spokesperson, Reuters
- “The WTA's women's eligibility policy is designed to promote equal athletic opportunities in women's professional tennis and maintain fair competition for all players participating in WTA tournaments,” — WTA statement, BBC
- “Since first being introduced in 1975, the eligibility policy has undergone periodic review in light of developments across international sport.” — WTA statement, BBC
